Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Lexeo Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy

by Seini Moimoi | Aug 1, 2023 | Portfolio News

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

by Seini Moimoi | Jul 24, 2023 | Portfolio News

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

by Seini Moimoi | Jul 10, 2023 | Portfolio News

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

by Seini Moimoi | Jun 24, 2023 | Portfolio News

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

by Seini Moimoi | Jun 17, 2023 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer